Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants

Current Medical Research and Opinion

Volumn 30, Issue 8, 2014, Pages 1513-1520

  Laliberté, François ^a   Coleman, Craig I ^b,c   Bookhart, Brahim ^d   Lefebvre, Patrick ^a   Cloutier, Michel ^a   Damaraju, C V ^d   Schein, Jeffery R ^d   Kaatz, Scott ^e  

^a Groupe d'Analyse Ltee   (Canada)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e HURLEY MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Recurrence; Risk; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RECURRENT DISEASE; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; AGED; EVALUATION STUDY; FACTUAL DATABASE; LONGITUDINAL STUDY; ORAL DRUG ADMINISTRATION; PULMONARY EMBOLISM; RETROSPECTIVE STUDY; RISK; TREATMENT OUTCOME; VENOUS THROMBOSIS; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DATABASES, FACTUAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RECURRENCE; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84904876358     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.915801     Document Type: Article

References (22)

1. Heit JA, Cohen AT, Anderson Frederick AJ; on Behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. ASH Annu Meet Abstr 2005;106:910
2. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160(6):761-8
3. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
4. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997;337:657-62
5. Hansson P, Sö rbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74
6. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29:298-310
7. Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost 2008;100:780-8
8. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010;170:1710-16
9. White RH, Murin S, Wun T, et al. Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. J Thromb Haemost 2010;8:987-97
10. Palareti G. Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) 2012;2012:1-17
11. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th edn, American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419-94S
12. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
13. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
14. Büller HR, Prins MH, Lensin AWA, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
15. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
16. Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15
17. Sambath KA, Ramanujam R, Chinnaiyan P. Survival analysis: Kaplan-Meier and life table estimates for time to event clinical trial tuberculosis data. Concepts Pure Appl Sci 2013;1:17-21
18. Limone BL, Hernandez AV, Michalak D, et al. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. Thromb Res 2013;132:420-6
19. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. Haematologica 2007;92:199-205
20. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25
21. Caine GJ, Stonelake PS, Lip GYH, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002;4:465-73
22. Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167:1471-5